Cargando…

Pharmacists are initiators in palliative care for patients with rare diseases

The World Health Organization supports early delivery of palliative care as it reduces unnecessary hospital admissions and the inappropriate use of health care services. A community pharmacist can play a key role in advocating timely access to palliative care. Medication reconciliation must alert th...

Descripción completa

Detalles Bibliográficos
Autor principal:	Dooms, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Position Statement
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249311/ https://www.ncbi.nlm.nih.gov/pubmed/37291601 http://dx.doi.org/10.1186/s13023-023-02765-8

Ejemplares similares

Compounded medication for patients with rare diseases
por: Dooms, Marc, et al.
Publicado: (2018)

Palliative Care in Coronavirus Disease 2019 Pandemic: Position Statement of the Indian Association of Palliative Care
por: Damani, Anuja, et al.
Publicado: (2020)

Orphan medical devices have come a long way
por: Dooms, M.
Publicado: (2023)

Orphan devices: yesterday is history; tomorrow is mystery: towards a European orphan device directive?
por: Dooms, Marc M
Publicado: (2016)

International Association for Hospice and Palliative Care Position Statement: Euthanasia and Physician-Assisted Suicide
por: De Lima, Liliana, et al.
Publicado: (2017)

Position statement on access to care in rare liver diseases: advancements of the European reference network (ERN) RARE-LIVER
por: Bernts, Lucas H. P., et al.
Publicado: (2019)

Providing high-quality care remotely to patients with rare bone diseases during COVID-19 pandemic
por: Brizola, E., et al.
Publicado: (2020)

Sharing is caring: a call for a new era of rare disease research and development
por: Denton, Nathan, et al.
Publicado: (2022)

European expert network on rare communicable diseases and other rare diseases linked to mobility and globalisation focused on health care provision (EURaDMoG): a feasibility study
por: Requena-Méndez, Ana, et al.
Publicado: (2020)

Epidemiology of rare diseases in Brazil: protocol of the Brazilian Rare Diseases Network (RARAS-BRDN)
por: Félix, Têmis Maria, et al.
Publicado: (2022)

eHealth for patients with rare diseases: the eHealth Working Group of the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN)
por: Paglialonga, Alessia, et al.
Publicado: (2021)

A patient advocating for transparent science in rare disease research
por: Yang, Richard Rui
Publicado: (2023)

Data silos are undermining drug development and failing rare disease patients
por: Denton, Nathan, et al.
Publicado: (2021)

Rare diseases in Tanzania: a National Call for Action to address policy and urgent needs of individuals with rare diseases
por: Kaywanga, Frida, et al.
Publicado: (2022)

RD-RAP: beyond rare disease patient registries, devising a comprehensive data and analytic framework
por: Bellgard, Matthew I., et al.
Publicado: (2019)

From scientific discovery to treatments for rare diseases – the view from the National Center for Advancing Translational Sciences – Office of Rare Diseases Research
por: Kaufmann, Petra, et al.
Publicado: (2018)

Rare disease education in Europe and beyond: time to act
por: Tumiene, Birute, et al.
Publicado: (2022)

Rare diseases in Chile: challenges and recommendations in universal health coverage context
por: Encina, Gonzalo, et al.
Publicado: (2019)

Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures
por: Morel, Thomas, et al.
Publicado: (2017)

European Reference networks for rare diseases: what is the conceptual framework?
por: Héon-Klin, Véronique
Publicado: (2017)

Increasing African genomic data generation and sharing to resolve rare and undiagnosed diseases in Africa: a call-to-action by the H3Africa rare diseases working group
por: Lumaka, Aimé, et al.
Publicado: (2022)

Recommendations from the IRDiRC Working Group on methodologies to assess the impact of diagnoses and therapies on rare disease patients
por: Zanello, Galliano, et al.
Publicado: (2022)

Pharmaceutical pricing, cost containment and new treatments for rare diseases in children
por: Stella, Peter, et al.
Publicado: (2014)

Clinical management guidelines for Friedreich ataxia: best practice in rare diseases
por: Corben, Louise A., et al.
Publicado: (2022)

European reference network for rare vascular diseases (VASCERN) consensus statement for the screening and management of patients with pathogenic ACTA2 variants
por: van de Laar, Ingrid M. B. H., et al.
Publicado: (2019)

Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases
por: Douglas, Conor M. W., et al.
Publicado: (2022)

The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks
por: Evangelista, Teresinha, et al.
Publicado: (2016)

The need for widely available genomic testing in rare eye diseases: an ERN-EYE position statement
por: Black, Graeme C., et al.
Publicado: (2021)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders
por: Mulberg, Andrew E., et al.
Publicado: (2019)

TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases
por: Annemans, Lieven, et al.
Publicado: (2020)

A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs
por: Cui, Yazhou, et al.
Publicado: (2015)

European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT)
por: Shovlin, Claire L., et al.
Publicado: (2018)

Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)
por: Annemans, Lieven, et al.
Publicado: (2017)

Integrating rare disease management in public health programs in India: exploring the potential of National Health Mission
por: Choudhury, Mohua Chakraborty, et al.
Publicado: (2022)

Clinical development innovation in rare diseases: lessons learned and best practices from the DevelopAKUre consortium
por: Rudebeck, Mattias, et al.
Publicado: (2021)

ACMT Position Statement: Caring for Patients with Opioid Use Disorder during Coronavirus Disease Pandemic
por: Stolbach, Andrew, et al.
Publicado: (2020)

Towards the international interoperability of clinical research networks for rare diseases: recommendations from the IRDiRC Task Force
por: Nabbout, Rima, et al.
Publicado: (2023)

Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease
por: Spineli, Loukia M., et al.
Publicado: (2017)

The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases – recommendations of the IRDiRC Data Mining and Repurposing Task Force
por: Southall, Noel T, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c8n6ondvccad1vhgi22tusi52f